However, for efficient in vivo targeting, a tumor-associated antigen fused to TAT-NHR2 may be required, as was successfully demonstrated for a TAT-p53-derived protein targeting cells overexpressing the CXCR4 receptor [51]. Here, TP53 is linked to neoplasm.